ArcticZymes Technologies — Investor Presentation 2023

Dec 14, 2023

DNB Nordic Healthcare Conference

CEO Michael Akoh CFO Børge Sørvoll

ArcticZymes Technologies ASA

Shaped by the Arctic – Global outreach

• A global leading specialist supplier of novel enzymes
• 20+ years' experience
• HQ in Tromsø, Norway
• 60+ employees
• Direct sales in most markets
• Publicly listed, OSE:AZT

A Growing Market

Targeting high-growth Biomanufacturing and Molecular diagnostics segments

Biomanufacturing Focus on Cell & Gene Therapies

Market Size 2023 – 2030 5 Bil USD – 30 Bil USD Nucleases: 500 million US dollars (CAGR 20%)

Bio-manufacturing

• Enzymes utilized in the production process of gene therapy (viral vectors)
• FDA expects more 200 INDs/year and 10- 20 approvals/year from 2025 within CGT

Molecular diagnostics

Enzymes for driving assay technologies and innovation

• New technologies and chemistry driving growth

Molecular Tools Molecular Research & Diagnostics

Market Size 2023 – 2027 23 – 30 Bil USD (CAGR. 5.4%)

Our Solutions

Unique enzymes for applications in the workflow

Nucleic Acid Extraction, Amplification and Sequencing technologies Cell & Gene therapy (viral vectors); RNA therapeutics (mRNA vaccines) SAN (Salt Active Nuclease) HQ family Shrimp Alkaline Phosphatase Cod Uracil DNA Glycosylase Endo- & Exo-Nucleases IsoPol™ Polymerases Ligases Proteinases M-SAN HQ Molecular Tools (Molecular Diagnostics & Research) Reverse Transcriptases DNA Polymerases Biomanufacturing (Therapeutics)

Spotlight SAN (Salt Active Nuclease)

Product Placement - Biomanufacturing

Case Study – viral vector manufacturing (CGT)

Introducing SAN HQ GMP

Salt Active Nuclease with superior performance

• The Salt & Nuclease Paradox:
• As salt concentration increases, conditions for DNA clearance improve, but enzyme function decreases
• This "paradox" is resolved by SAN HQ GMP
• Ability to clear DNA from viral vectors increases as salt concentration rises

Growing the Biomanufacting segment Through regulatory complaince – GMP and DMF

Growing the SAN business

GMP grade production expands addressable market

Financial Performance

Financial Performance

Organisation

Recruitment drive completed

Well postioned to deliver long term growth

Attractive market space

• Operating in growth segments
• New therapies within CGT and mRNA

Strong Foundation

• Strong cash position and high margins
• Experienced team
• Reputation and security of supply
• Global sales channels customer base
• Pipeline

Growth leverage

• Organic growth but with an eye out for M&A
• Innovation driven by biotechnology toolbox
• Compliance upgrade to GMP / DMF